New radiation technique aims to hit harder, harm less in metastatic cancer

NCT ID NCT05880667

Recruiting now Disease control Sponsor: Fox Chase Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase I trial tests adaptive stereotactic body radiation (SBRT) for people with cancer that has spread to the abdomen or pelvis. The goal is to safely deliver higher radiation doses to tumors while keeping severe side effects under 10%. Thirty participants will receive this tailored radiation approach to see if it is both feasible and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adaptive stereotactic body radiation (SBRT)
What this could lead to: If successful, this approach could allow safer, more effective radiation treatment for hard-to-treat metastatic tumors in the abdomen or pelvis.
What could go wrong: This is an early Phase I trial with only 30 participants, so results may not apply broadly. The main risk is severe side effects from higher radiation doses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM OF STOMACH are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm malignant soft tissue neoplasm metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM OF STOMACH NEOPLASM - SOFT TISSUE PELVIS MALIGNANT SECONDARY

Contacts and locations

Locations

Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.